




Searching News Database: Bystolic
HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
HSMN NewsFeed - 22 Jul 2013
Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC(R) Patent Litigation
Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC(R) Patent Litigation
HSMN NewsFeed - 23 Feb 2010
Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic(R)
Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic(R)
HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension